131 related articles for article (PubMed ID: 12699058)
1. Quantitative assessment of HER-2/neu protein concentration in breast cancer by enzyme-linked immunosorbent assay.
Müller V; Thomssen C; Karakas C; Eustermann I; Ramirez Porras J; Coith C; Berger J; Löning T; Jänicke F; Pantel K
Int J Biol Markers; 2003; 18(1):13-20. PubMed ID: 12699058
[TBL] [Abstract][Full Text] [Related]
2. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.
Konecny G; Pauletti G; Pegram M; Untch M; Dandekar S; Aguilar Z; Wilson C; Rong HM; Bauerfeind I; Felber M; Wang HJ; Beryt M; Seshadri R; Hepp H; Slamon DJ
J Natl Cancer Inst; 2003 Jan; 95(2):142-53. PubMed ID: 12529347
[TBL] [Abstract][Full Text] [Related]
3. HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.
Pectasides D; Gaglia A; Arapantoni-Dadioti P; Bobota A; Valavanis C; Kostopoulou V; Mylonakis N; Karabelis A; Pectasides M; Economopoulos T
Anticancer Res; 2006; 26(1B):647-53. PubMed ID: 16739334
[TBL] [Abstract][Full Text] [Related]
4. HER-2 protein concentrations in breast cancer cells increase before immunohistochemical and fluorescence in situ hybridization analysis turn positive.
Olsen DA; Østergaard B; Bokmand S; Wamberg PA; Jakobsen EH; Brandslund I
Clin Chem Lab Med; 2007; 45(2):177-82. PubMed ID: 17311504
[TBL] [Abstract][Full Text] [Related]
5. Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status.
Madrid MA; Lo RW
Breast Cancer Res; 2004; 6(5):R593-600. PubMed ID: 15318940
[TBL] [Abstract][Full Text] [Related]
6. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples.
Tanner M; Gancberg D; Di Leo A; Larsimont D; Rouas G; Piccart MJ; Isola J
Am J Pathol; 2000 Nov; 157(5):1467-72. PubMed ID: 11073807
[TBL] [Abstract][Full Text] [Related]
7. Determination of her-2/neu by chromogenic in situ hybridization on borderline (2+) immunohistochemistry cases in carcinoma breast.
Asif M; Khadim MT; Mushtaq S; Mamoon N; Akhtar F; Ali Z
Asian Pac J Cancer Prev; 2011; 12(1):211-4. PubMed ID: 21517259
[TBL] [Abstract][Full Text] [Related]
8. Chromogenic in situ hybridization for Her-2/neu-oncogene in breast cancer: comparison of a new dual-colour chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization.
Mayr D; Heim S; Weyrauch K; Zeindl-Eberhart E; Kunz A; Engel J; Kirchner T
Histopathology; 2009 Dec; 55(6):716-23. PubMed ID: 19922593
[TBL] [Abstract][Full Text] [Related]
9. Her-2/neu gene amplification and protein expression in primary male breast cancer.
Rudlowski C; Friedrichs N; Faridi A; Füzesi L; Moll R; Bastert G; Rath W; Büttner R
Breast Cancer Res Treat; 2004 Apr; 84(3):215-23. PubMed ID: 15026619
[TBL] [Abstract][Full Text] [Related]
10. Enzyme-linked immunosorbent assay of HER-2/neu gene product (p185) in breast cancer: its correlation with sex steroid receptors, cathepsin D and histologic grades.
Marsigliante S; Muscella A; Ciardo V; Barker S; Leo G; Baker V; Mottaghi A; Vinson GP; Storelli C
Cancer Lett; 1993 Dec; 75(3):195-206. PubMed ID: 7906196
[TBL] [Abstract][Full Text] [Related]
11. Relevance of p185 HER-2/neu oncoprotein quantification in human primary breast carcinoma.
Bermont L; Algros MP; Baron MH; Adessi GL
Breast Cancer Res Treat; 2000 Sep; 63(2):163-9. PubMed ID: 11097092
[TBL] [Abstract][Full Text] [Related]
12. Stability of HER-2/neu expression over time and at multiple metastatic sites.
Niehans GA; Singleton TP; Dykoski D; Kiang DT
J Natl Cancer Inst; 1993 Aug; 85(15):1230-5. PubMed ID: 8101229
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of the quantitative assessment of the cytosolic concentration of HER-2/neu protein in breast cancer by immunoenzymatic assay (ELISA).
Corte MD; Rodil JA; Vázquez J; García L; Rodríguez JC; Bongera M; Fernández JC; González LO; Lamelas ML; Allende M; García-Muñiz JL; Fueyo A; Vizoso FJ
J Cancer Res Clin Oncol; 2005 Nov; 131(11):701-14. PubMed ID: 16075281
[TBL] [Abstract][Full Text] [Related]
14. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
[TBL] [Abstract][Full Text] [Related]
15. Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her-2/neu (erbB-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptin) in breast cancer cells with Her-2/neu oncogene amplification.
Menendez JA; Vellon L; Colomer R; Lupu R
Ann Oncol; 2005 Mar; 16(3):359-71. PubMed ID: 15642702
[TBL] [Abstract][Full Text] [Related]
16. HER-2/neu overexpression in breast cancer: an immunohistochemical study including correlations with clinicopathologic parameters, p53 oncoprotein and cathepsin-D.
Korkolis D; Ardavanis A; Yotis J; Kyroudi A; Gorgoulis V; Kittas C
Anticancer Res; 2001; 21(3C):2207-12. PubMed ID: 11501848
[TBL] [Abstract][Full Text] [Related]
17. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.
Pauletti G; Dandekar S; Rong H; Ramos L; Peng H; Seshadri R; Slamon DJ
J Clin Oncol; 2000 Nov; 18(21):3651-64. PubMed ID: 11054438
[TBL] [Abstract][Full Text] [Related]
18. Her-2/neu amplification and breast cancer survival: results from the Shanghai breast cancer study.
Beeghly-Fadiel A; Kataoka N; Shu XO; Cai Q; Deming SL; Gao YT; Zheng W
Oncol Rep; 2008 May; 19(5):1347-54. PubMed ID: 18425397
[TBL] [Abstract][Full Text] [Related]
19. Her-2/neu oncogene amplification and protein over-expression in interval and screen-detected breast cancers.
Anttinen J; Kuopio T; Nykanen M; Torkkeli H; Saari U; Juhola M
Anticancer Res; 2003; 23(5b):4213-8. PubMed ID: 14666627
[TBL] [Abstract][Full Text] [Related]
20. HER-2/neu oncogene amplification by chromogenic in situ hybridization in 130 breast cancers using tissue microarray and clinical follow-up studies.
Chang E; Lee A; Lee E; Lee H; Shin O; Oh S; Kang C
J Korean Med Sci; 2004 Jun; 19(3):390-6. PubMed ID: 15201505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
